|
|
Post by orlon on Jul 6, 2017 20:24:38 GMT -5
I don't quite see the same confidence in Mannkind as I did several years ago, or indeed just last year. It appears to me that what has had to be said has been said, what had to be done has been done. I like many others who have lost more than a few dollars in the company, are simply waiting for the inevitable. But claiming 3k/yr loss on my 1040 over the next 10 years (I'll be 83 by then) is a little consolation.
|
|
|
|
Post by deaner3 on Jul 6, 2017 21:44:35 GMT -5
Ironically everyone is different.
I was excited about stock in 2014/2015
Became bummed and numb to it from 2016 to April 2017
But have been more bullish than ever before from this past May To now. Really went all in and averaged down. Super excited.
But can relate with how you feel because I was there not that long ago. But think bottom was in awhile back. And we will see a steady increase going forward. I'm confident that the shares I bought at FDA approval will be green someday. Will take a long time. But all shares will eventually be green.
|
|
|
|
Post by mytakeonit on Jul 6, 2017 22:52:06 GMT -5
If you are deducting losses on your 1040, then you already sold your shares and watching on the sidelines for MNKD bankruptcy "for the inevitable"? Or, do you still own shares?
I'm in a situation more like Deaners and averaged down. I'm also expecting great things to happen soon!
|
|
|
|
Post by kc on Jul 6, 2017 23:26:17 GMT -5
If you are deducting losses on your 1040, then you already sold your shares and watching on the sidelines for MNKD bankruptcy "for the inevitable"? Or, do you still own shares? I'm in a situation more like Deaners and averaged down. I'm also expecting great things to happen soon! I sold last year in September and purchase back 32 days later following the rules for a wash sale. I still believe in the product and I hope we turn the corner very soon. I Actually have more shares than I did last year before I sold for a loss. |
|
|
|
Post by slugworth008 on Jul 6, 2017 23:46:23 GMT -5
I have every stinking share still - lol. Averaged down again a good bit when we hit 1.86 (pre- R/S) told myself I'd sell those shares at 2.25...we'll we got to 2.23 and I still have them. A painful experience to be sure, however I see light at the end of the tunnel now and am optimistic that my pre-adcom 7.26 shares will def be green someday though the 5/1 really sucked. Did I think we'd be in this position in 2015 - Hell No.....but Afrezza IS a game changer and I'm def holding. July/Aug are going to be significant months for MNKD. I surely wish Mike and team the best of fortunes.
And I've already got my 3K write-off in place from another stock from several years ago - FWIW
|
|
|
|
Post by factspls88 on Jul 7, 2017 9:05:59 GMT -5
At this point there's not much left to say. It's do or die. We'll see what happens after Reversed builds an audience, but if insurance is still a problem and Afrezza doesn't get a label change , it's gonna be tough to see any light at the end of the tunnel. Yet still I hold a ton of shares. Sigh.
|
|
|
|
Post by orlon on Jul 7, 2017 10:27:34 GMT -5
I still own shares but another loss today, possibly below $1.00 next week and the inevitable collapse by the end of the year. I've had this company in my portfolio for years and no longer see any optimism.
|
|
|
|
Post by sportsrancho on Jul 7, 2017 11:00:25 GMT -5
I still own shares but another loss today, possibly below $1.00 next week and the inevitable collapse by the end of the year. I've had this company in my portfolio for years and no longer see any optimism. Let's see what Mike says at the next CC:-) ER |
|
|
|
Post by ilovekauai on Jul 7, 2017 11:16:46 GMT -5
Counter-punch doomsayers all over the board today. I mentioned this war is far from over. I can take a gut-punch and a lot more. Hang tough Longs. There's no "inevitable collapse by the end of the year" happening. Let Michael C get this squared away. He will, trust me. Do not despair. It always seems darkest before the dawn, always! Our success is coming & we will win this planned attack & war on Afrezza that we find ourselves in. Have a great weekend; relax a little & enjoy this lovely Summer weather!
|
|
|
|
Post by myocat on Jul 7, 2017 11:31:54 GMT -5
i put in $1.10 order, anyone who has less confident, sells shares to me.
|
|
|
|
Post by tw12 on Jul 7, 2017 11:50:19 GMT -5
ilovekauai:
I too can't help but encourage doomsayers to chill.
Pure and simple, we've invested in a fabulous product (and more to come) with a proprietary and well protected technology; a smart, experienced and fully committed team behind it; and a huge market in front.
Yes, it's been a tough road but, IMHO, the powerful, we-know-your-struggle messaging that is soon to come will override any resistance. I, for one, can't wait to witness the reality, within two or three years, of this planet's 400+ million T1's and T2's living happily with Afrezza -- thanks to Al Mann and the hundreds of good folks working hard to make it happen.
|
|
|
|
Post by ilovekauai on Jul 7, 2017 11:56:43 GMT -5
Mahalo for a terrific post TW12! So well stated! Onwards!
|
|
|
|
Post by silentknight on Jul 7, 2017 12:27:30 GMT -5
Optimism is important in investing. Why else would an investor sink money into a company unless they believed in it and thought it to be a good investment? If they thought it likely the company would struggle, they'd be short.
I agree that there are reasons to be optimistic. We've seen Brazil become an new potential area for Afrezza to take hold, given time, and there COULD be potential important milestones approaching with a label change and DTC advertising if we ever see them. I have completely written off any potential positives from Epi, RLS, or anything else MNKD seems to have indicated they were working on, so they've put all their eggs in one basket: Afrezza.
It's also important to remember that many of the things that people claim to be reasons for optimism can also be looked at as reasons to be extremely skeptical of the company and doubtful of their ability to deliver. Afrezza has been on the market under MNKD's control and brand for over a year now and while the company has made strides in putting many things in place, according to the script numbers, they're no closer to achieving significantly better sales today than we've seen in the past. Yes, going up a few percentage points is laudable and increasing revenue is important, but if those new numbers are still mere fractions of what is needed to be truly successful at this point then it has all been for naught in my opinion.
One could argue that MNKD has had qualified and experienced people around them for many many years. That certainly didn't help the company in achieving success post FDA approval. Al Mann was a visionary and was successful by any standard, but he too failed to make Afrezza's potential success a reality. Matt devoted many years to MNKD and was just as qualified as Mike to be CEO. Frankly, I'm waiting for Mike Castagna to deliver on sales or meaningful improvements as CEO. I have been extremely unimpressed with his performance to date. Drive and passion, two attributes that he displays admirably, are not tools to measure success. Only results do that.
MNKD needs sales. Period. Until and if they can deliver sales that are worthly of the caliber of drug that Afrezza actually is, I will remain skeptical of those calling the shots. The Board of Directors for MNKD have laughed all the way to the bank while they've watched shareholders pay the price for their mistakes after mistakes. That won't soon be forgotten by me and likely many other longs, not at least until my investment shows green, if we ever see that day.
|
|
|
|
Post by factspls88 on Jul 7, 2017 13:37:27 GMT -5
"One could argue that MNKD has had qualified and experienced people around them for many many years. That certainly didn't help the company in achieving success post FDA approval. Al Mann was a visionary and was successful by any standard, but he too failed to make Afrezza's potential success a reality. Matt devoted many years to MNKD and was just as qualified as Mike to be CEO. Frankly, I'm waiting for Mike Castagna to deliver on sales or meaningful improvements as CEO. I have been extremely unimpressed with his performance to date. Drive and passion, two attributes that he displays admirably, are not tools to measure success. Only results do that." With all due respect to Al, Matt, and Hakan and what they were able to accomplish, they did not have the skill set to market Afrezza and make it commercial. Al recognized that fact, hence the partnership with Sanofi. Matt did a great job keeping the company alive and hiring someone like Mike, but he is a finance guy and not a pharma marketer. Hakan is a scientist, not a marketer. As we have learned the hard way, launching a new drug, particularly one with mass market potential is highly complex, particularly considering all the hurdles involved - the FDA for label approval/change, endocrinologists, general practitioners, and the myriad of insurance companies and government agencies (e.g. Medicare). Marketing to those constituencies requires experience with all of them as well as a keen knowledge of and experience in direct to consumer pharma marketing. And just as Mike would likely not make a great finance guy or scientist, neither would Matt nor Hakan make great general managers in pharma marketing. I say this as someone with prior experience as a senior marketing manager in consumer products as well as a consultant to Fortune 500 companies. Despite that experience in market strategy, I would be woefully ill-equipped to launch a pharma brand like Afrezza. So I have been willing to give Mike a chance. But as we all know the clock has been and is ticking. I suppose I should have sold a while ago, but I didn't so at this point I have little choice but to let this ride out and see what happens - perhaps a miracle  |
|
|
|
Post by saxcmann on Jul 7, 2017 14:32:12 GMT -5
"One could argue that MNKD has had qualified and experienced people around them for many many years. That certainly didn't help the company in achieving success post FDA approval. Al Mann was a visionary and was successful by any standard, but he too failed to make Afrezza's potential success a reality. Matt devoted many years to MNKD and was just as qualified as Mike to be CEO. Frankly, I'm waiting for Mike Castagna to deliver on sales or meaningful improvements as CEO. I have been extremely unimpressed with his performance to date. Drive and passion, two attributes that he displays admirably, are not tools to measure success. Only results do that." With all due respect to Al, Matt, and Hakan and what they were able to accomplish, they did not have the skill set to market Afrezza and make it commercial. Al recognized that fact, hence the partnership with Sanofi. Matt did a great job keeping the company alive and hiring someone like Mike, but he is a finance guy and not a pharma marketer. Hakan is a scientist, not a marketer. As we have learned the hard way, launching a new drug, particularly one with mass market potential is highly complex, particularly considering all the hurdles involved - the FDA for label approval/change, endocrinologists, general practitioners, and the myriad of insurance companies and government agencies (e.g. Medicare). Marketing to those constituencies requires experience with all of them as well as a keen knowledge of and experience in direct to consumer pharma marketing. And just as Mike would likely not make a great finance guy or scientist, neither would Matt nor Hakan make great general managers in pharma marketing. I say this as someone with prior experience as a senior marketing manager in consumer products as well as a consultant to Fortune 500 companies. Despite that experience in market strategy, I would be woefully ill-equipped to launch a pharma brand like Afrezza. So I have been willing to give Mike a chance. But as we all know the clock has been and is ticking. I suppose I should have sold a while ago, but I didn't so at this point I have little choice but to let this ride out and see what happens - perhaps a miracle Exactly! Great Post! Same boat probably like many here... |
|
